New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
19:17 EDTCRS, FIVE, VRA, DELL, TTMI, PCRX, CBKOn The Fly: After Hours Movers
UP AFTER EARNINGS/GUIDANCE: Vera Bradley (VRA), up 9.7% after raising its Q4, FY12 EPS views... Christopher & Banks (CBK), up 8.4% after raising its Q4 SSS view... TTM Technologies (TTMI), up 6.8% after providing Q4 EPS and revenue guidance within range of Street... DOWN AFTER EARNINGS/GUIDANCE: Five Below (FIVE), down 1.8% despite raising its Q4 guidance... Pacira Pharmaceuticals (PCRX), down 4.6% after providing Q4, FY12 revenue guidance... Carpenter Technology (CRS), down 6% after providing Q2 EPS, revenue guidance below Street estimates... ALSO LOWER: Dell (DELL), down 1.2% after CNBC's David Faber reported a buyout deal for the company would likely be worth $13.50-$14 per share.
News For VRA;CBK;TTMI;FIVE;PCRX;DELL;CRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 26, 2015
09:03 EDTFIVEFive Below Q4 results should help rebuild confidence, says UBS
Subscribe for More Information
07:12 EDTFIVEFive Below price target raised to $41 from $35 at MKM Partners
Subscribe for More Information
06:31 EDTPCRXPacira announces positive data in study of Exparel
Subscribe for More Information
March 25, 2015
18:33 EDTFIVEOn The Fly: After Hours Movers
UP AFTER EARNINGS: Red Hat (RHT), up 4.6%... Five Below (FIVE), up 5.5%. ALSO HIGHER: Pernix Therapeutics (PTX), up 2.4% after being initiated with an Outperform at Oppenheimer. DOWN AFTER EARNINGS: Verint Systems (VRNT), down 2.3%... Pacific Sunwear (PSUN), down 5.9%. ALSO LOWER: Sucampo (SCMP), down 9.5% after filing to sell Class A common stock for holders... FutureFuel (FF) down 8% after "significant adverse impact" of P&G pact termination... Genesee & Wyoming (GWR), down 1.3% after lowering first quarter revenue guidance.
16:08 EDTFIVEFive Below down 3.8% after reporting Q4 results, lower than expected guidance
16:07 EDTFIVEFive Below sees FY15 EPS $1.02-$1.05, consensus $1.08
Subscribe for More Information
16:05 EDTFIVEFive Below sees Q1 EPS 6c-7c, consensus 8c
Sees Q1 revenue $150M-$152M, consensus $154.24M. Sees Q1 SSS up 1%-2%. Sees 18 new stores opening in Q1.
16:04 EDTFIVEFive Below reports Q4 EPS 61c, consensus 60c
Reports Q4 revenue $236.8M, consensus $262.22M. Reports Q4 SSS up 3.2%.
15:34 EDTFIVENotable companies reporting after market close
Subscribe for More Information
07:05 EDTFIVEFive Below April volatility elevated into Q4 and outlook
Subscribe for More Information
March 24, 2015
19:40 EDTCBKOn The Fly: After Hours Movers
Subscribe for More Information
16:15 EDTCBKChristopher & Banks reports Q4 EPS 86c, may not compare to consensus (10c)
Q4 EPS included a $41.3M, or $1.10 per diluted share, reversal of the valuation allowance related to deferred income taxes and the impact of the error correction of $2.2M, or 6c per diluted share.
16:07 EDTCBKChristopher & Banks says calculation of deferred rent expense incorrect
Subscribe for More Information
16:06 EDTCBKChristopher & Banks sees FY15 revenue $422M-$432M, consensus $438.56M
Subscribe for More Information
16:04 EDTCBKChristopher & Banks sees Q1 net sales $90M-$94M, consensus $108.18M
Expects Q1 gross margin to decline by 140-160 basis points, with continued improvement in merchandise margins more than offset by deleveraging of occupancy and other cost of goods sold. Inventory for the first quarter is expected to be lower, on average, than last year, but end the quarter approximately 4.0% higher than at the end of last year’s first quarter.
16:03 EDTCBKChristopher & Banks reports Q4 EPS 86c, may not compare to consensus (10c)
Subscribe for More Information
10:01 EDTFIVEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:48 EDTFIVEFive Below initiated with a Buy at Buckingham
Target $39.
March 23, 2015
16:32 EDTPCRXPacira announces results of two data presentations for Exparel
Pacira Pharmaceuticals announced results of two data presentations on the impact of Exparel on postsurgical opioid requirements in patients undergoing hysterectomy or mastectomy. The data were presented during two poster sessions at the annual meeting of the International Anesthesia Research Society, or IARS, being held in Honolulu March 21-24. The first study compared the efficacy of Exparel to bupivacaine HCl when infiltrated into the transversus abdominis plane, or TAP, to provide postsurgical analgesia following robotic assisted hysterectomy in 60 women. Blinded assessments of pain intensity, opioid intake and incidence of adverse events were taken for up to 72 hours after the procedure. In comparison to the bupivacaine HCl treatment group, patients who received TAP infiltration with Exparel had: Significantly decreased total opioid intake in first 72 hours; Significantly decreased incidence of nausea and vomiting in the first 72 hours; Significantly lower maximal pain intensity at all time points.
March 20, 2015
10:07 EDTFIVEHigh option volume stocks
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use